NEW YORK (Reuters Health)—Adding high-dose teriparatide to denosumab therapy leads to substantially greater increases in bone-mineral density (BMD) than combination therapy with low-dose teriparatide, a new phase 4 study shows. “The combination of denosumab and teriparatide, particularly with high-dose teriparatide of 40 ug daily, may be of benefit to patients at very high risk of…
No Gain with Pain: Exercise & Physical Function in Patients with Rheumatic Disease
Pain can deter patients with rheumatic disease from engaging in physical activity. But the latest research shows exercise helps reduce pain, & other influences may also affect patients’ activity levels, particularly after surgery…
Stay the Course: How to Maintain Remission in Vasculitis
MADRID—During the 2019 European Congress of Rheumatology (EULAR), held June 12–15, speakers addressed the complexity of vasculitis in a Challenges in Clinical Practice session titled, How to Maintain Remission in Vasculitis. Although vasculitis appears in many varieties, one commonality exists among these related yet distinct conditions: When there is vital organ or systemic involvement, disease…
Calling Young Rheumatologist Leaders
The ACR’s delegation to the AMA is seeking applicants to be a second Young Physician Section representative for the ACR.
Updates to Axial Spondyloarthritis Guideline
A 2019 update of the ACR’s previous clinical practice guideline on axial spondyloarthritis is now available online. Lead investigator Michael Ward, MD, shares advice for implementing the guideline updates, including those related to sequencing and tapering biologics, and knowing when to obtain images.
ACR on Air: New Rheumatology Podcast Introduced
A new podcast from the ACR provides in-depth discussions about newly published science, regulatory updates, advocacy and volunteer opportunities for the rheumatology community…
FDA Approves Upadacitinib for RA
Results from multiple phase 3 clinical trails have led to the FDA approval of upadacitinib to treat patients with moderate to severe active RA…
Rituximab-Induced Serum Sickness Is More Frequent in Autoimmune Diseases
Recent research into rituximab-induced serum sickness (RISS) reinforces the understanding that patients generally recover quickly. However, the study also found patients with autoimmune disease, especially SLE, had a significantly higher risk for developing RISS than patients using rituximab to treat hematological malignancy…
Practice Matters: New Workshop Will Provide Insights into Practice Management at the 2019 ACR/ARP Annual Meeting
Technology, billing, regulations—how do rheumatologists manage the business side of their practices in an ever-changing environment? During this year’s Annual Meeting, a practical, full-day workshop will offer attendees the tools to thrive in today’s healthcare business landscape…
Intensive, Personalized Learning
During the 2019 ACR/ARP Annual Meeting, the new Meet the Professor Workshops and sessions will feature hands-on training on state-of-the-art topics…
- « Previous Page
- 1
- …
- 235
- 236
- 237
- 238
- 239
- …
- 806
- Next Page »